At Speer Medical Technologies, our effective and innovative technology platform is a heavily-researched and refined form of targeted radionuclide therapy based on attaching potent high LET radionuclides to targeting constructs which are molecules capable of isolating and binding cancer cells. The targeting construct then brings the radioisotopes to cancer cells where the radiation can efficiently identify and eliminate the targeted cancer cell.

Because high LET radiation is far more thorough and effective than using beta particles, Speer Medical Technologies utilizes this form of radiation to effectively kill cancers that are not sensitive to beta radiation. Additionally, the high LET radiation used in this form of targeted radionuclide therapy has an extremely short treatment range which greatly limits damage inflicted to healthy tissues adjacent to cancer cells.

If you have any questions regarding our innovative proprietary technology or our research into the field of oncology, we invite you to Contact Us today.